Search results
Showing 31 to 45 of 78 results for psoriasis
This guideline sets out an antimicrobial prescribing strategy for secondary bacterial infection of eczema and covers infection of other common skin conditions. It aims to optimise antibiotic use and reduce antibiotic resistance. The recommendations are for adults, young people and children aged 72 hours and over. They do not cover diagnosis.
Risankizumab for treating active psoriatic arthritis after inadequate response to DMARDs (TA803)
Evidence-based recommendations on risankizumab (Skyrizi) for treating active psoriatic arthritis in adults.
Evidence-based recommendations on certolizumab pegol (Cimzia) and secukinumab (Cosentyx) for treating active psoriatic arthritis in adults.
Tofacitinib for treating active psoriatic arthritis after inadequate response to DMARDs (TA543)
Evidence-based recommendations on tofacitinib (Xeljanz) for treating active psoriatic arthritis in adults after inadequate response to DMARDs.
Ixekizumab for treating active psoriatic arthritis after inadequate response to DMARDs (TA537)
Evidence-based recommendations on ixekizumab (Taltz) for treating active psoriatic arthritis in adults.
Upadacitinib for treating active psoriatic arthritis after inadequate response to DMARDs (TA768)
Evidence-based recommendations on upadacitinib (Rinvoq) for treating active psoriatic arthritis in adults.
Guselkumab for treating active psoriatic arthritis after inadequate response to DMARDs (TA815)
Evidence-based recommendations on guselkumab (Tremfya) for active psoriatic arthritis after inadequate response to DMARDs in adults.
Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis (TA199)
Evidence-based recommendations on etanercept (Enbrel), infliximab (Remicade) and adalimumab (Humira) for treating active and progressive psoriatic arthritis in adults.
View recommendations for TA199Show all sections
This quality standard covers diagnosing and managing spondyloarthritis in adults aged 16 and over. It describes high-quality care in priority areas for improvement.
Grenz rays therapy for inflammatory skin conditions (HTG151)
Evidence-based recommendations on Grenz rays therapy for inflammatory skin conditions. This involves exposing the skin to low-energy, non-penetrative electromagnetic radiation.
View recommendations for HTG151Show all sections
Sections for HTG151
Secukinumab for treating active ankylosing spondylitis (TA407)
Evidence-based recommendations on secukinumab (Cosentyx) for treating active ankylosing spondylitis.
Evidence-based recommendations on ustekinumab (Stelara) for treating active psoriatic arthritis in adults.
View recommendations for TA340Show all sections
Evidence-based recommendations on bimekizumab (Bimzelx) for treating active psoriatic arthritis in adults.